Researchers from the Laboratory of Cancer Metabolism at IDIBELL found a potential target for the treatment of type 2 diabetes. The study is published in the Journal of Clinical Investigation. Research led by Sara Kozma, have shown in animal models that inhibition of S6K1 protein may be a potential treatment for type 2 diabetes.



